Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma

NCT01582776 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

317

Enrollment

OTHER

Sponsor class

Conditions

Follicular Lymphoma Patients (Phase IB)
Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II)

Interventions

DRUG: Lenalidomide and GA101

Sponsor

The Lymphoma Academic Research Organisation